Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

KRS Pioneers Optogenetics Tools

This article was originally published in Start Up

You may also be interested in...



Optogenetics: Start-Ups Head For The Light

Optogenetics – technology to control neurons with light – has swept through basic neuroscience research. Efforts to commercialize optogenetics are complex, but a spunky group of start-ups plan to develop therapies using the technology.

Don’t Believe The Rice

After reading a paper in Cell Research that showed a microRNA produced in rice could modulate gene expression in the livers of mice that consumed it, Bill Marshall, PhD, chief scientific officer of RNA-therapeutics company miRagen Therapeutics Inc., began drawing up a business plan around the technology.

Check Again: The Problem With Reproducibility

Promising academic results prove elusive when the experiments are run again, threatening reputations and wasting industry resources. Everyone is scrambling for a fix, but is the problem as bad as it seems, and do we really need a top-down solution?

Topics

Latest News
UsernamePublicRestriction

Register

SC092553

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel